Search results
London close: Stocks finish mixed at start of busy week
ShareCast· 3 days agoLondon stocks closed with mixed results on Monday, reflecting a cautious market sentiment ahead of a...
Breast cancer drug not recommended for NHS use after price talks break down
Greenock Telegraph· 3 days agoThe National Institute for Health and Care Excellence (Nice) said it is “deeply disappointed” it was unable to recommend trastuzumab deruxtecan – sold under the brand name Enhertu – due to company ...
Breast cancer drug REJECTED for NHS as TV star slams 'heartbreaking' decision
The Sun· 3 days agoIts makers, Daichii Sankyo and AstraZeneca, said they had offered a secret deal cheaper than what...
FTSE 100 movers: AstraZeneca in the black; Reckitt tumbles
ShareCast· 3 days agoLondon’s FTSE 100 was up 0.3% at 8,309.79 in afternoon trade on Monday.
Breast cancer drug not recommended for NHS use after price talks break down
The Irish News· 3 days agoA life-extending drug for incurable breast cancer will not be made available on the health service...
Issuers Pile Into Europe’s Primary Market Before Key Risk Events
Bloomberg· 3 days agoHave a confidential tip for our reporters? Debt sales in Europe’s primary market were at a brisk...
AstraZeneca reports positive results from leukaemia drug trial
ShareCast· 3 days agoAstraZeneca has hailed positive high-level results from a clinical trial of its Calquence treatment...
1 FTSE 100 bargain stock I love
Motley Fool UK· 4 days agoOne outcome of all that investment activity is the stock market’s rarely taken completely by surprise when Footsie firms report their trading results and...
Ossett school mums bond over shared cancer journey
BBC News· 5 days agoFor Debbie Holland and Sarah Sykes what began as a friendship forged at the school gates has evolved into a much deeper bond as they support each other...
Bristol Myers surges 10%, its biggest increase since 2008, after boosting profit forecast
Business Insider via Yahoo Finance UK· 5 days ago"We saw good growth in the first half [of the decade], and we expect good growth in the back half,"...
